ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2846

Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility

Smitha Reddy1, Dana Copland Reddy2, Rufus Burlingame3, Vicki Nelson4, Carol Buchner4, John Stewart5, Sasi Mudumba5, John Custodio5, Jue Wang5, Randy Romero5, Alice Wu6, Carli Cherwein5, Simon Smith5 and Martin A. Gleeson4, 1Arthritis Care and Research Center, San Diego, CA, 2SD Rheumatology, Chula Vista, CA, 3Genaltye, San Diego, CA, 4Genalyte, Wateridge circle, CA, 5Genalyte, San Diego, CA, 6Genalyte, Inc., San Diego, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ANA and Diagnostic Tests

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Multiplex assays that measure anti-nuclear autoantibodies (ANA) in real time using whole blood were developed on the Maverick(TM) instrument (Genalyte, Inc., USA). Because the assay takes less than 10 minutes to complete, it would be possible to perform the test in a near patient setting in an outpatient clinic. The purpose of this study was to evaluate the feasibility of using this novel instrument to perform ANA 8 tests in the clinic and to compare those results to the same sample tested in Genalyte’s CLIA registered laboratory.

Methods: An Institutional Review Board (IRB) application was approved so that patients who were seeing a rheumatologist and were going to be tested for ANA using the clinics’ standard lab testing procedures could also volunteer to donate additional venous and/or finger-stick blood for further testing. Both the venous and finger-stick blood were immediately tested on the ANA 8 on the Maverick instrument in the clinic. This multiplex immunoassay measures autoantibodies to SS-A 60, SS-B, Sm, Sm/RNP, Scl-70, Jo-1, centromere B and dsDNA. The cutoff between negative and positive was standardized so that 40 AU and greater are positive. Even though results were available in real time, the protocol specified that the doctor would not be given results until the end of the study. 154 samples of venous blood were collected, tested on the Maverick and then returned to the Genalyte CLIA lab for processing into serum for comparison testing on the FIDIS Connective 10 (Theradiag, France). In addition, 54 samples of finger-stick blood were also collected for comparison testing.

Results: The results between whole blood finger stick (WBFS) and whole blood venous (WBVN) tested on the Maverick, and serum tested on the FIDIS for positive, negative and total agreement are shown in the table below.

 

Positive Agreement Among 8 Markers

Negative Agreement Among 8 Markers

Total Agreement Among 8 Markers

WBFS vs WBVN

100%

98% to 100%

98% to 100%

WBFS vs FIDIS

100%

96% to 100%

96% to 100%

WBVN vs FIDIS

100%

97% to 100%

97% to 100%

  The r2 correlation between the values for all of the 8 ANA markers from finger stick (54 times 8 yields 432 results) versus venous whole blood is 0.98 as shown below.

Conclusion: This pilot study demonstrated the feasibility of performing multiplex ANA testing on whole blood in a near patient setting in an outpatient clinic.  There is extremely high correlation for absolute value between venous blood and finger-stick blood, and between positive and negative results seen with whole blood on the Maverick and serum on the FIDIS.  While further studies are required to quantify the impact such a diagnostic system might have on quality of care, there is potential for such a capability to improve timeliness of diagnosis, increase patient centricity and reduce overall healthcare resource utilization.  


Disclosure: S. Reddy, None; D. Copland Reddy, Abbvie, 8; R. Burlingame, Genalyte, Inc., 3; V. Nelson, Genalyte, 3; C. Buchner, Genalyte, 3; J. Stewart, Genalyte, 3; S. Mudumba, Genalyte, 3; J. Custodio, Genalyte, 3; J. Wang, Genalyte, 3; R. Romero, Genalyte, 3; A. Wu, Genalyte, 3; C. Cherwein, Genalyte, 3; S. Smith, Genalyte, 3; M. A. Gleeson, Genalyte, 3.

To cite this abstract in AMA style:

Reddy S, Copland Reddy D, Burlingame R, Nelson V, Buchner C, Stewart J, Mudumba S, Custodio J, Wang J, Romero R, Wu A, Cherwein C, Smith S, Gleeson MA. Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/application-of-a-novel-anti-nuclear-antibody-multiplex-test-using-finger-stick-and-venous-whole-blood-in-a-rheumatology-clinic-demonstration-of-feasibility/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/application-of-a-novel-anti-nuclear-antibody-multiplex-test-using-finger-stick-and-venous-whole-blood-in-a-rheumatology-clinic-demonstration-of-feasibility/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology